TOKYO & NEW YORK & DÜSSELDORF, Germany, June 13, 2024--(BUSINESS WIRE)--Asahi Kasei has announced that in April 2024 it began selling a membrane system to produce WFI (water for injection), a type of sterile water that is used for the preparation of injections.
Asahi Kasei moves to buy Calliditas for more than $1B
Asahi Kasei to Acquire Calliditas Therapeutics AB to Accelerate Growth as a Global Healthcare Company
Asahi Kasei to buy Swedish drugmaker Calliditas for $1.1 billion
Asahi Kasei Bioprocess to Unveil THESYS™ ACS ERGO Synthesis Column at TIDES USA
Asahi Kasei Bioprocess (AKB) has unveiled the THESYS ACS ERGO synthesis column, its latest oligo manufacturing innovation which offers reduced changeover time between batches while maintaining user safety and product quality.
Asahi Kasei Bioprocess and Axolabs Announce Strategic Partnership to Accelerate Oligonucleotide Therapeutics Development
Asahi Kasei Bioprocess’ Massachusetts Training Center Expands 2024 Course Offerings for Career Development and Industry Training
Asahi Kasei offers Ceolus microcrystalline cellulose (MCC) with nitrite levels of 0.1 ?g/g (ppm) or less to contribute to reducing the risk of potentially carcinogenic nitrosamine impurities in pharmaceuticals and nutritional supplements.
Asahi Kasei Offers Pharmaceutical Excipient Ceolus™ with Nitrite Concentration of 0.1 ppm or Less